Observational study on the change of clonal heterogeneity by afatinib or gefitinib treatment using next generation sequencing analysis and the effect of osimertinib as a secondary treatment (CHASE study) - Observational study on the change of clonal heterogeneity by afatinib or gefitinib treatment using next generation sequencing analysis and the effect of osimertinib as a secondary treatment (CHASE study)

Hyogo Cancer Center0 个研究点目标入组 40 人开始时间: 2018年8月31日最近更新: 2023年10月17日

试验速览

暂无简介。

•1)Administrated other EGFR-TKI before afatinib or gefitinib treatment as 1st line therapy 2)Administrated afatinib or gefitinib as 1st line therapy and recieved other anti-tumor medicine after disease progression before prior to osimertinib therapy 3)Interstitial lung disease or pulmonary fibrosis 4)Active double cancers 5)Uncontrolled abdominal or pericardial effusion or ascites 6)With the following severe comorbidities -Uncontrolled angina, cardiac infarct within three month, or heart failure -Uncontrolled diabetes or hypertension -Severe infection or comorbidities -Significant or recent gastrointestinal disorders whose main symptom is diarrhea -Other complications (e.g. ileus) judged to pose serious obstacles to osimeltinib therapy 7)Women who are pregnant, planning to become pregnant, or breast-feeding. Patients who are unwilling to use contraceptives 8)Patients whose physician assessed inappropriate to the study

发起方